Opthea Stock News

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company''s Chief Executive Officer, will present at Oppenheimer''s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022. The presentation will be available beginning Tuesday, March 15, at 8:40 am ET (11:40 pm AEDT), and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/ . About Opthea Limited Opthea ((ASX:OPT, NASDAQ: OPT ) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea''s lead product candidate OPT-302 … Full story available on Benzinga.com

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retin

Opthea (OPT) has appointed Dr. Joel Naor as Chief Medical Officer, effective 1 March 2022. Dr

Opthea Limited''s (NASDAQ: OPT ) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in … Full story available on Benzinga.com

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Companys Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022.

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre

Opthea (OPT) received a A$6.6M (or $4.9M) R&D tax credit from the Australian Taxation Office which is for the cost incurred in FY20-FY21 and it represents the amount disclosed in…

MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retina

Zacks Investment Research downgraded shares of Opthea (NASDAQ:OPT) from a buy rating to a hold rating in a research report report published on Saturday, Zacks.com reports. According to Zacks, “Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, Australia. […]

Opthea Limited (NASDAQ:OPT) saw a large decrease in short interest in October. As of October 29th, there was short interest totalling 97,400 shares, a decrease of 36.8% from the October 14th total of 154,000 shares. Based on an average daily volume of 12,400 shares, the days-to-cover ratio is currently 7.9 days. Separately, Zacks Investment Research []

MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre

Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD)

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre

The big gain appears to be a sympathy move related to positive news for another drugmaker.

MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre